WO2023021319 - MONOCLONAL ANTIBODIES AGAINST HER2/NEU AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2023/021319
Publication Date
23.02.2023
International Application No.
PCT/IB2021/057644
International Filing Date
19.08.2021
Title **
[English]
MONOCLONAL ANTIBODIES AGAINST HER2/NEU AND USES THEREOF
[French]
ANTICORPS MONOCLONAUX DIRIGÉS CONTRE HER2/NEU ET LEURS UTILISATIONS
Applicants **
ONCOQUEST PHARMACEUTICALS INC.
Inventors
MADIYALAKAN, Ragupathy
WOO, Thomas
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3000 | |
| EPO | Filing, Examination, Granting | 25731 | |
| Japan | Filing, Examination, Granting | 2958 | |
| South Korea | Filing, Examination, Granting | 2657 | |
| USA | Filing, Examination, Granting | 12540 |
Total:
46,886
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present document describes an antibody or an antigen-binding fragment comprising three variable heavy domain complementarity determining regions (CDR) (CDR H1, H2 and H3) that binds specifically to Her2/Neu. The present invention also relates to pharmaceutical compositions, nucleic acid molecule, vectors, cells comprising the nucleic acid vectors, and methods of treating Her2/Neu associated diseases.[French]
La présente invention concerne un anticorps ou un fragment de liaison à l'antigène comprenant trois régions déterminant la complémentarité de domaine lourd (CDR) variables (CDR H1, H2 et H3) qui se lient de manière spécifique à Her2/Neu. La présente invention concerne également des compositions pharmaceutiques, une molécule d'acide nucléique, des vecteurs, des cellules comprenant les vecteurs d'acide nucléique, et des méthodes de traitement de maladies associées à Her2/Neu.